EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Insights into RAS-driven melanoma and its therapeutic implications

Eftychia Chatziioannou, Konstantinos Lallas, Tobias Sinnberg, Heike Niessner, Alexander J Stratigos, Lukas Flatz, Teresa Amaral

Cancer Treatment Reviews · 2026

DOI: 10.1016/j.ctrv.2026.103090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Eftychia Chatziioannou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, ras Proteins, GTP Phosphohydrolases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 223 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NRAS mutations are present in 15-25 % of cutaneous melanomas, predominantly affecting codon 61 (Q61R > Q61K). Mutations at codons 12 and 13 are rare although they appear to be relatively enriched in mucosal subtype. KRAS alterations, while rare in cutaneous melanomas, are more frequently observed in melanoma brain metastases as well as in acral and mucosal subtypes, where NRAS mutations are less prevalent. For advanced RAS-mutant melanoma, systemic therapy currently relies on anti-PD-1-based immune checkpoint inhibition. MEK inhibitors have demonstrated only modest clinical benefit due to the development of resistance and are not approved outside of China for this subtype. Ongoing combination strategies include MEK inhibition with type II RAF inhibitors (naporafenib plus trametinib in phase III trial), ERK1/2 or ERK5 inhibitors, PI3K/mTOR pathway blockade, or CDK4/6 inhibition. Additional investigational approaches include mutation-specific RAS inhibitors (G12C inhibitors already approved for other cancers), NRAS-specific or pan-RAS inhibitors (daraxonrasib in phase III trial for other cancers), targeted protein degradation, RAS-directed peptide and mRNA vaccines (mRNA-4157). NRAS Q61K-derived neoepitopes bound to HLA-A*01:01 have been recognized as immunogenic, suggesting that mutation-specific immunotherapies could represent a promising future strategy. In conclusion, the advent of promising and emerging therapies is set to transform the management of RAS-driven melanoma, making a personalized, biomarker-informed treatment strategy essential for optimizing patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin Neoplasmsras ProteinsGTP PhosphohydrolasesHumansMutationMolecular Targeted TherapyMembrane Proteins

Stichwörter der Autor:innen

Immune checkpoint inhibitorsMelanomaMolecular targeted therapyRAS

Substanzen

ras ProteinsGTP PhosphohydrolasesNRAS protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany.
  • Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Department of Medical Oncology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Tübingen, Germany.
  • Department of Dermatology, University of Athens Medical School, Andreas Syggros Hospital, Athens, Greece.
  • Department of Dermatology, University Hospital Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Department Dermatology and Allergology, Kantonsspital St. Gallen 9007 St. Gallen, Switzerland.
  • Early Phase Clinical Trials Unit, Strasbourg Europe Cancer Institute, Stransbourg, France. Electronic address: t.amaral@institut-strauss.fr.

Zitieren

APA

Chatziioannou, E., Lallas, K., Sinnberg, T., Niessner, H., Stratigos, A. J., Flatz, L., & Amaral, T. (2026). Insights into RAS-driven melanoma and its therapeutic implications. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103090

Vancouver

Chatziioannou E, Lallas K, Sinnberg T, Niessner H, Stratigos AJ, Flatz L, et al. Insights into RAS-driven melanoma and its therapeutic implications. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2026.103090

BibTeX
@article{Chatziioannou2026,
  author = {Chatziioannou, Eftychia and Lallas, Konstantinos and Sinnberg, Tobias and Niessner, Heike and Stratigos, Alexander J and Flatz, Lukas and Amaral, Teresa},
  title = {Insights into RAS-driven melanoma and its therapeutic implications},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  doi = {10.1016/j.ctrv.2026.103090}
}
Kostenlos starten →